4 documents found, page 1 of 1
Modulation of brain structure and motor function by safinamide multimodal actio...
Araújo, Bruna; Campos, Jonas; Silva, Rita Caridade; Pinheiro, Bárbara Mendes; Marques, Raquel; Barata, Sandra; Lima, Rui; Macedo, Joana MartinsTo date, no neuroprotective/disease-modifying strategy has been approved as a Parkinson’s Disease (PD) therapy, because of the‘one-disease-one-target’ view that has been followed. New drug-based therapeutic routes, namely Safinamide, have been introduced as a promising multimodal drug combining dopaminergic and non-dopaminergic (neuroprotective) actions, representing a new potential alternative therapy to preve...
Microglial depletion has no impact on disease progression in a mouse model of m...
Campos, Ana Bela; Silva, Sara Carina Duarte; Fernandes, Bruno; Coimbra, Bárbara; Campos, Jonas; Monteiro-Fernandes, Daniela; Teixeira-Castro, AndreiaMachado–Joseph disease (MJD), also known as spinocerebellar ataxia type 3 (SCA3), is an autosomal dominant neurodegenerative disorder (ND). While most research in NDs has been following a neuron-centric point of view, microglia are now recognized as crucial in the brain. Previous work revealed alterations that point to an increased activation state of microglia in the brain of CMVMJD135 mice, a MJD mouse model ...
Fractionating stem cells secretome for Parkinson's disease modeling: Is it the ...
Vilaça-Faria, Helena; Marote, Ana; Lages, Inês; Ribeiro, Clarisse; Mendes-Pinheiro, Bárbara; Domingues, Ana Verónica; Campos, Jonas; Lanceros-Méndez, S.Human mesenchymal stem cells (hMSCs) secretome has been have been at the forefront of a new wave of possible therapeutic strategies for central nervous system neurodegenerative disorders, as Parkinson's disease (PD). While within its protein fraction, several promising proteins were already identified with therapeutic properties on PD, the potential of hMSCs-secretome vesicular fraction remains to be elucidated...
Preclinical comparison of stem cells secretome and levodopa application in a 6-...
Teixeira, Fábio G.; Vilaça-Faria, Helena; Domingues, Ana V.; Campos, Jonas; Salgado, A. J.Parkinson’s Disease (PD) is characterized by the massive loss of dopaminergic neurons, leading to the appearance of several motor impairments. Current pharmacological treatments, such as the use of levodopa, are yet unable to cure the disease. Therefore, there is a need for novel strategies, particularly those that can combine in an integrated manner neuroprotection and neuroregeneration properties. In vitro an...